Acquisition of blood-brain barrier penetration technology and intellectual property through the acquisition of ArmaGen

A standalone M&A transaction involving the acquisition of ArmaGen as a wholly owned subsidiary and the acquisition of intellectual property and technology assets, including patents covering blood-brain barrier (BBB) penetration technology. The theme is to strengthen the drug development platform for compounds capable of crossing into the brain by using the acquired assets.